Drug
ECC4703 clinical trials
Also written ECC4703.
- studies test it
- 5
- open now
- 3
- in phase 3
- 0
- first study started
- 2022
Keep track of what changes. Save the ECC4703 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
5 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 2
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Eccogene (5)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ECC4703 is read from its arms, and is right about nine times in ten.
Testing it · 5
- A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)RecruitingPhase 2EccogeneNCT07288138Written as ECC4703
- ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult ParticipantsRecruitingPhase 1EccogeneNCT07334080Written as ECC4703 F0 formulation
- Study of ECC4703 With Sulfasalazine and PitavastatinRecruitingPhase 1EccogeneNCT07726368Written as ECC4703
- MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) TrialActive, not recruitingPhase 2EccogeneNCT07505303Written as ECC4703
- FTIH of ECC4703 in Healthy VolunteersCompletedEarly Phase 1EccogeneNCT05552274Written as ECC4703